Jasper Therapeutics Inc (JSPR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.71+3.23%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · JSPR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
JSPR — earnings miss
Dated 2026-08-14
Results of Operations and Financial Condition. On August 14, 2026, Jasper Therapeutics, Inc. issued a press release reporting its financial results for the quarter ended June 30, 2026 and providing a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instructions B.2 of Form 8-K, the information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is being furnished under
Why it matters: This data will show how well KP-104 works in rare renal disorders. Positive results could boost confidence in the drug's potential.
Supportive ifInterim data from Stage 1 of the Phase 2 trial shows good results.
Worry ifInterim data from Stage 1 of the Phase 2 trial shows poor results or safety issues.
Why it matters: The earnings report will show if Jasper is doing better or worse.
Watch forEarnings show a big drop in losses from earlier quarters.
Also watch forEarnings report shows bigger losses or no change in financial health.
Why it matters: An FDA meeting could lead to a Phase 3 study for KP-104, crucial for its market potential.
Supportive ifAnnouncement of plans for an end-of-Phase 2 meeting with the FDA in H1 2027.
Worry ifNo announcement regarding the FDA meeting plans by the end of H1 2027.
Why it matters: Compliance with Nasdaq listing rules is critical for the company's stock. A delisting could hurt investor confidence.
Worry ifThe company confirms it meets the $1.00 bid price requirement.
Less concerning ifThere may be a notice of delisting or not meeting compliance rules.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$383 on $10,000 · ±3.8% | How much price usually moves either way. |
| Bad day | $936 loss on $10,000 · 9.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,746 loss on $10,000 · 87.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The company received a notice for not meeting the minimum bid price. Compliance is crucial for continued listing.
Worry ifThe company announced it is back in line with Nasdaq listing rules.
Less concerning ifNasdaq sent more notice about ongoing non-compliance.
Why it matters: Jasper received a notice for not meeting the $1.00 bid price requirement. This could impact stock stability.
Worry ifSuccessful actions helped the stock price rise above $1.00.
Less concerning ifThe stock still does not meet the $1.00 minimum bid price requirement.
Why it matters: Progress towards a pre-BLA meeting shows briquilimab is moving forward for SCID. This may mean good news from regulators.
Supportive ifManagement says they had a good meeting with the FDA.
Worry ifManagement delays or cancels the meeting with the FDA.
Why it matters: A new indication could expand KP-104's market potential and validate its therapeutic profile. This would be a key milestone for the company.
Supportive ifManagement confirms a new indication for KP-104 is announced by the end of 2026.
Worry ifNo announcement is made regarding a new indication for KP-104 by year-end.